RPS6KA6

Across TCGA pan-cancer cohorts, RPS6KA6 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated RPS6KA6 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher RPS6KA6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS6KA6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

MESO, UCEC, and BLCA are the cancer types where RPS6KA6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
UCEC	DFS	Median	All	0.930	0.611	.005	28	view →
BLCA	DFS	Median	II,III,IV	0.928	0.602	.009	14	view →
PAAD	OS	Median	II,III,IV	0.205	0.556	.002	12	view →
LIHC	DFS	Median	All	0.115	0.545	.001	12	view →
LUAD	OS	Median	II,III,IV	0.079	0.677	<.001	10	view →
ACC	DFS	Median	All	0.089	0.666	.010	9	view →
SKCM	DFS	Median	II,III,IV	0.837	0.673	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RPS6KA6–MESO (OS)

Open the MESO breakdown →